Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and antiinflammatory agents

Details for Australian Patent Application No. 2008206231 (hide)

Owner TAP PHARMACEUTICAL PRODUCTS

Inventors McDonald, Patricia; Taneja, Rajneesh; Lademacher, Christopher; Ridge, Nancy J.

Agent Griffith Hack

Pub. Number AU-A-2008206231

PCT Pub. Number WO2008/089296

Priority 60/881,794 19.01.07 US

Filing date 17 January 2008

Wipo publication date 24 July 2008

International Classifications

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Event Publications

13 August 2009 PCT application entered the National Phase

  PCT publication WO2008/089296 Priority application(s): WO2008/089296

17 September 2009 Alteration of Name

  The name of the applicant has been altered to Takeda Pharmaceuticals, North Amercia, Inc.

26 April 2012 Alteration of Name

  The name of the applicant has been altered to Takeda Pharmaceuticals U.S.A., Inc. 2009

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008206239-Advanced pattern recognition systems for spectral analysis

2008206221-Stable reagents and kits useful in loopmediated isothermal amplification (LAMP)